This study is testing a drug called trastuzumab deruxtecan (T-DXd) in adults with metastatic breast cancer that was previously treated. Metastatic means the cancer has spread from its original site. While your breast cancer may be considered HER2-negative, this study aims to see if T-DXd can still be helpful for you. T-DXd is an antibody-drug conjugate, which means it combines an antibody (trastuzumab) that targets cancer cells with a cancer-fighting medicine (deruxtecan). This combination is designed to attack cancer cells while being gentler on healthy cells. Researchers will be looking at how many participants respond to the treatment. The study plans to enroll 40 participants, but its current status is unclear.

Study design

This is an interventional study with an enrollment goal of 40 participants. It is testing the drug trastuzumab deruxtecan.

What's involved

Participants will receive trastuzumab deruxtecan by IV infusion every 21 days. The number of treatments will depend on how you respond.

Compensation

Not stated in the trial record.

Follow-up

The primary outcome, Objective Response Rate, is measured after cycle 3, which is approximately 63 days.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.